Potential of Diabetes Medications in Treating Alcohol Use Disorder
Emerging research suggests that diabetes drugs targeting GLP-1 and GIP receptors may help reduce alcohol consumption and improve liver health, promising new avenues for alcohol use disorder treatment.
Recent research indicates that medications traditionally used for managing diabetes, specifically GLP-1 and GIP receptor agonists, may hold promise in addressing alcohol use disorder (AUD). A large-scale genetic analysis conducted by scientists at the National Institute on Alcohol Abuse and Alcoholism explored the influence of these hormones on alcohol consumption behaviors and liver health. By applying drug-target Mendelian randomization — a method that leverages genetic data to predict drug effects — researchers found that naturally occurring variations affecting GLP1R and GIPR genes were associated with reduced binge drinking and lower risk of heavy alcohol use. Notably, these genetic proxies for lowered BMI and appetite regulation correlated with decreased alcohol intake and preferences for healthier foods, such as vegetarian options, as well as improved liver function indicators like reduced NAFLD and ALT levels.
The findings suggest that drugs targeting GLP-1 and GIP receptors, already used for obesity and diabetes, could potentially be repurposed to treat AUD. This approach could also influence appetite and cravings, offering a dual benefit in managing both alcohol consumption and metabolic health. While the study did not directly test the effects of these medications on humans with AUD, it provides a foundational understanding that could guide future clinical trials. The potential to reduce hazardous drinking and improve liver health emphasizes the importance of exploring these hormonal pathways further.
Overall, this research highlights the innovative use of genetic data to identify new therapeutic avenues for alcohol use disorder, opening doors to more effective and targeted treatments in the future.
Source: https://medicalxpress.com/news/2025-10-diabetes-drugs-treatment-alcohol-disorder.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Addressing Gaps in Hepatitis C Treatment Among Vulnerable Populations
Recent research highlights disparities in hepatitis C treatment among children and pregnant women, emphasizing the need for targeted strategies to eliminate the virus and improve care for vulnerable populations.
Breakthrough in Cancer Precision Therapy: Identifying Patients Who Benefit from Bexmarilimab
A new study unveils how bexmarilimab activates the immune system against cancer and introduces a gene signature for selective patient treatment, advancing personalized immunotherapy.
Breakthrough Monoclonal Antibody Offers New Hope in Sepsis Treatment
A novel monoclonal antibody developed by scientists at UVA and Michigan shows promise in preventing sepsis by stopping cytokine storms, with potential for broader inflammatory disease treatment.
Innovative Method for Measuring Aging Speeds Enhances Understanding of Healthspan and Lifespan in Older Adults
A new method for measuring the Pace of Aging improves prediction of health risks and enhances understanding of aging trajectories in older adults, supporting better health interventions and policies.